Press Releases

- Phase 3b dosing of ARCT-154 initiated; study designed to enroll approximately 20,000 participants - Initiation of Phase 3b study follows review of safety data from initial 1,000 Phase 1/2/3a participants - ARCT-154 remains on track for Emergency Use Authorization (EUA) filing in December 2021 SAN

SAN DIEGO --(BUSINESS WIRE)--Sep. 22, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

Phase 1 (100 participants): both doses completed Phase 2 (300 participants) has initiated Phase 3a (600 participants) on track to initiate by end of September Phase 3b (20,000 participants) dosing planned for first week of October ARCT-154 remains on track for Emergency Use Authorization (EUA)

SAN DIEGO --(BUSINESS WIRE)--Sep. 8, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

SAN DIEGO --(BUSINESS WIRE)--Sep. 7, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory

ARCT-021, Arcturus’ single shot STARR™ mRNA COVID vaccine, to begin multinational placebo-controlled Phase 3 efficacy study funded and sponsored by a global entity ARCT-154, Arcturus’ STARR™ mRNA vaccine candidate targeting COVID variants of concern, elicits robust neutralizing antibody titers

Singapore is the second country to approve the advancement of ARCT-154 into clinical development ARCT-154 and ARCT-165 elicit high levels of neutralizing antibodies in non-human primates against multiple variants of concern SAN DIEGO --(BUSINESS WIRE)--Aug.

The Phase 1/2/3 trial to be funded and sponsored by Arcturus’ manufacturing partner Vinbiocare ARCT-154 to be developed in parallel with ARCT-021, Arcturus’ lead investigational COVID-19 vaccine SAN DIEGO --(BUSINESS WIRE)--Aug. 2, 2021-- Arcturus Therapeutics Holdings Inc.

Arcturus will receive $40 million upfront payment and potential royalties based on vaccines produced SAN DIEGO --(BUSINESS WIRE)--Aug. 2, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the

SAN DIEGO --(BUSINESS WIRE)--Jul. 28, 2021-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT) a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory